The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1137-1145 , May 2010

Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?

Received 25 June 2009 ,Revised 7 September 2009 ,Accepted 1 October 2009.

References 

  1. Carabello BA. What is new in the 2006 ACC/AHA guidelines on valvular heart disease?. Curr Cardiol Rep. 2008;10:85–90
  2. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48:e1–e148
  3. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230–268
  4. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111–1119
  5. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg. 2005;129:1024–1031
  6. Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg. 2008;33:531–536
  7. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation. 1989;80:1501–1513
  8. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol. 1986;8:41B–56B
  9. Douglas PS, Hirshfeld JW, Edie RN, Harken AH, Stephenson LW, Edmunds LH. Clinical comparison of St. Jude and porcine aortic valve prostheses. Circulation. 1985;72:II135–II139
  10. Hartz RS, Fisher EB, Finkelmeier B, DeBoer A, Sanders JH, Moran JM, et al. An eight-year experience with porcine bioprosthetic cardiac valves. J Thorac Cardiovasc Surg. 1986;91:910–917
  11. Goldsmith I, Turpie AG, Lip GY. Valvar heart disease and prosthetic heart valves. Bmj. 2002;325:1228–1231
  12. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2004;127:1166–1170
  13. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110:496–500
  14. Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation—risk of thromboembolism. Thorac Cardiovasc Surg. 1995;43:212–214
  15. Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998;98:II95–II99
  16. Kalbfleisch P. The Statistical Analysis of Failure Time Data (Wiley Series in Probability and Statistics). Hoboken, NJ: John Wiley & Sons; 1980;
  17. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:457S–482S
  18. Orszulak TA, Schaff HV, Mullany CJ, Anderson BJ, Ilstrup DM, Puga FJ, et al. Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg. 1995;59:462–468
  19. Blair KL, Hatton AC, White WD, Smith LR, Lowe JE, Wolfe WG, et al. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation. 1994;90:II214–II219
  20. Aramendi JL, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis. 1998;7:610–614
  21. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res. 1973;5:167–179
  22. Virchow R. Cellular Pathology. London: Churchill; 1860;
  23. Dumesnil JG, Pibarot P. Prosthesis-patient mismatch and clinical outcomes: the evidence continues to accumulate. J Thorac Cardiovasc Surg. 2006;131:952–955
  24. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation. 2003;108:983–988
  25. Rao V, Jamieson WR, Ivanov J, Armstrong S, David TE. Prosthesis-patient mismatch affects survival after aortic valve replacement. Circulation. 2000;102:III5–III9
  26. Tasca G, Brunelli F, Cirillo M, DallaTomba M, Mhagna Z, Troise G, et al. Impact of valve prosthesis-patient mismatch on left ventricular mass regression following aortic valve replacement. Ann Thorac Surg. 2005;79:505–510

 Disclosures: None.

PII: S0022-5223(10)00043-7

doi: 10.1016/j.jtcvs.2009.10.064

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1137-1145 , May 2010

Article Tools

* Image Usage & Resolution